| Title： | Chinese expert consensus on diagnosis and treatment of hepatocellular carcinoma with microvascular invasion(2024) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinicians, technicians and related teaching and research staff engaged in liver cancer related work in hospitals of all levels |
| Evidence classification method： | Ia Evidences are originated from the meta-analysis results of various RCTs Ib Evidences are originated from the results of at least one well-designed RCT IIa Evidences are originated from the results of at least one well-designed perspective non-RCT IIb Evidences are originated from the results of at least one well-designed interventional clinical research of other type III Evidences are originated from the well-designed non-interventional clinical researches, such as descriptive researches and relevant researches IV Evidences are originated from the reports made by committee of experts or the clinical reports of authoritative experts |
| Development unit： | Chinese Association of Liver Cancer(CALC) and Chinese Medical Doctor Association(CMDA) |
| Registration time: | 2024-01-18 |
| Registration number： | PREPARE-2024CN185 |
| Purpose of the guideline: | At present, there are still many controversies on the diagnosis, classification, prediction and treatment of MVI, and no consensus has been reached. Based on the existing evidence-based medical evidence, especially the clinical research results of Chinese scholars on HCC with MVI, the CALC reached this consensus after repeated discussion by members of the CALC. |
Latest registration
